SIMPLAAFY Clinical Trial
NCT: NCT06521463 · ACTIVE_NOT_RECRUITING
Publicidad
Resumen breve
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Fuente oficial
Ver en ClinicalTrials.gov →Datos obtenidos de la API de ClinicalTrials.gov. Para conocer el estado más reciente, consulte el registro oficial.